

SARC Biannual Meeting
 November 13, 2008
 The Landmark Hotel, London, UK
 8:00 am - 12:00 pm
AGENDA

8:00 – 8:15	Welcome/SARC Update	Laurence Baker <i>Chair, SARC Board of Directors</i>
8:15 – 8:45	Chawla/Rosenfeld Developmental Therapeutics Symposium (Part 1) Laboratory Investigation of Resistant GIST	Jonathan Fletcher
8:45– 10:15	Review of Ongoing SARC Trials	
	<ul style="list-style-type: none"> • SARC 003 Phase 2 Gemcitabine/Docetaxel in Bone Sarcoma • SARC 004 Phase 2 Neoadjuvant Imatinib in DFSP • SARC 005 Phase 2 Adjuvant Therapy High Risk Uterine Leiomyosarcoma • SARC 006 Phase 2 MPNST: Sporadic versus NF1 associated • SARC 007 Phase 2 Perifosine in chemoinensitive sarcoma • SARC 009 Phase 2 Dasatinib in metastatic sarcoma • SARC 011 Phase 2 IGF-1R in selected sarcomas • SARC011 Companion Biology Protocol • SARC 012 Phase 2 Src kinase Inhibitor Recurrent Osteosarcoma Localized to Lung 	<p>Lee Helman</p> <p>Scott Schuetze</p> <p>TBD</p> <p>Lee Helman</p> <p>Jonathan Trent</p> <p>Scott Schuetze</p> <p>Alberto Pappo</p> <p>Lee Helman</p> <p>Lee Helman*</p> <p>Su Kim</p>
10:15 – 10:45	Chawla/Rosenfeld Developmental Therapeutics Symposium (Part 2) New Approaches to GIST	Meg von Mehren
10:45—11:15	Review of Pending Trials	
	<ul style="list-style-type: none"> • SARC 013 Phase 3 IGF-1R/Ewings • SARC014 Phase 1 IGF-1R/Rapamycin • SARC015 Phase 2R1507 in WT GIST • SARC016 Phase 2 Everolimus/MPNST • SARC018 Phase 2 Surgery/Radiation 	<p>Herbert Jürgens*</p> <p>Paul Meyers</p> <p>Shreyas Patel</p> <p>Richard Gorlick</p> <p>Meg von Mehren</p> <p>Katie Janeway*</p> <p>Lee Helman</p> <p>Robert Benjamin</p>
11:00 – 11:30	SARC Restructuring	
	<ul style="list-style-type: none"> • Participating Committee • Medical Officer and New Concepts 	<p>Suzanne George</p> <p>Denise Reinke</p>
11:30-12:00	Closed Session: SARC Business Update (SARC Participants Only)	